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Introduction
Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders characterized by ineffective hematopoiesis, leading to blood cytopenias, and by a high risk of progression to acute myeloid leukemia (AML) 1 Activating mutations of oncogenes, and inactivating mutations of tumor suppressor genes have been identified in a number of genes in MDS and AML, although none of them identified mutations specific for MDS 4 . This include activating mutations of the RAS pathway 5 , as well as frequent methylation silencing of the CDKN2B (p15INK4B) gene 6 whereas TP53 (p53) mutations are less common 7 .
MDS can be viewed as a preleukemic condition in which apoptosis aborts the differentiation products of potentially malignant, mutated stem cells 8 9 . Low risk MDS (with low or int 1 IPSS) are characterized by increased intramedullary apoptosis of progenitors, leading to inefficient hematopoiesis and cytopenia. On the contrary, in high risk MDS (with int 2 or high IPSS), progressive increase in marrow blasts, with reduced apoptotic capacities, is seen, and blastic infiltration leads to cytopenias through marrow failure 10 . The cell death of
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Previous studies suggested that the expression of pro-apoptotic proteins (Bak, Bad, Bcl-X S )
has a positive prognostic value in MDS, while the expression of anti-apoptotic proteins (Bcl-2, Bcl-X L ) has a negative prognostic value 18 , suggesting that loss of the apoptotic program could favor the MDS --> AML transition.
The NF-κB family of transcription factors can potently suppress apoptosis 19 . Constitutive activation of NF-κB was reported for various solid tumors and hematological malignancies 20 21 . In multiple myeloma NF-κB activity leads to expression of the antiapoptotic protein Bcl-X L leading to chemoresistance. 22 Aberrant expression of NF-κB family proteins has been described for other B and T cell neoplasias, including in those induced by oncogenic viruses, namely Epstein Barr Virus (EBV) and HTLV-1, both of which encode NF-κB activators 23 24 .
Finally, NF-κB is found to be activated in primitive AML cells leading to expression of antiapoptotic c-IAP2 25 , through mechanisms that are not entirely elucidated.
Classically, the members of the NF-κB family form dimers (classically heterodimers of p65 with p50) which, under non-stimulated conditions, are retained in the cytoplasm through interactions with inhibitory molecules of the inhibitor of NF-κB (IκB) family 26 . Following activation by a number of stimuli that include cytokines, various stress signals, bacterial and viral products, the IκB molecules get phosphorylated by IκB kinases (IKK) and degraded by the ubiquitin-proteasome pathway 27 . This liberates the NF-κB dimers that are free to translocate to the nucleus and activate their target genes 28 . Inhibitors of NF-κB activation, notably inhibitors of IKK are being designed and undergo preclinical evaluation 29 .
Moreover, an indirect NF-κB inhibitor, bortezomib (Velcade   ®   ) , a proteasome inhibitor, has 
Patients, materials and methods
Patients
A total of 57 MDS patients and 7 healthy subjects were included in our study ( Table 1) .
Informed consent of all patients and healthy subjects was provided according to the Declaration of Helsinki. Approval for this study was obtained from the Institut Gustave Roussy institutional review board. MDS patients were previously untreated except supportive care. The diagnosis of MDS was based on peripheral blood counts, cytology of peripheral blood and bone marrow (BM) according to the WHO classification 2 and conventional cytogenetic analysis. These data permitted to evaluate the individual International Prognostic Scoring System (IPSS) score for each patient 3 . BM aspirates were obtained after informed consent into synringes containing media supplemented with EDTA.
The BM mononuclear cell (BMMNC) fraction was isolated by density gradient centrifugation using Ficoll-Paque TM PLUS (Amersham Biosciences).
Cells and culture conditions
The high risk MDS cell line P39/Tsugane (kindly provided by Dr Yoshida Takeda, Japan) was cultured in RPMI 1640 (Gibco) supplemented with 10% heat-inactivated Fetal Calf Serum, 2 mM L-glutamine, 100 IU/ mL penicillin, and 100 g/mL streptomycin as (Invitrogen) together with a T4 polynucleotide kinase (Roche) and incubated for 30 minutes at room temperature. Specificity was assessed by incubating nuclear extracts of treated cells with the non-radiolabeled NF-κB probe or mutated NF-κB probe (5'-ACAACTCACTTTCCGCTGCTCACTTTCCAG-3') (Invitrogen). In addition, we used a γ-32 P-labelled oligonculeotide probe specific for Oct-1 (Invitrogen) to determine equal loading
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Immunofluorescence
In separate experiments, 10 5 P39 or patient cells were allowed to adhere on polylisin-L coverslips (Sigma) and fixed in 4% paraformaldehyde at room temperature. Cells were then permeabilized either with Triton X-100 0,05% ( 
IκB measurement
Lysates obtained from 3.10 6 cells with or without prior exposure to 2.5 nM Bortezomib (Velcade ® ) were separated on 12% SDS-polyacrylamide gel and electroblotted onto nitrocellulose membranes. Blots were first stained with Phospho IκBα (mouse monoclonal Ab, CellSignalling) and revealed with anti-mouse peroxidase-labeled second Abs (Amersham). Revelation was performed using an enhanced chemiluminescence detection system (ECL, Amersham).
Fluorescence in situ hybridization (FISH)
Ex vivo BMMCs were allowed to adhere on polylysine -L glass slides (Sigma) and fixed in methanol/acetic acid (3:1) for 30 minutes or stained for nuclear p65 revealed by streptavidin/peroxidase after inhibition of endogenous peroxidases with 10% H 2 O 2 .
Interphase FISH was performed following manufacturer's instructions by using a rhodamine and fluorescein labeled dual probe (D7Z1/D8Z1) for simultaneous detection of the 
Results and Discussion
Constitutive NF-κB activation in the P39 cell line. The myelomonocytic P39 cell line, which has been derived from the bone marrow of an MDS/AML patient 42 , exhibits constitutive NF-κB activation, as determined by two different techniques, namely electrophoretic mobility shift assays (EMSA) (Fig. 1A, B) demonstrating the retention of NF-κB in nuclear DNA (which could be supershifted with a p65-specific antibody, Fig. 1B ), as well as immunofluorescence staining revealing the presence of the NF-κB subunit p65 in the nucleus (Fig. 1 C) . Pretreatment of P39 cells with three different inhibitors led to the disappearance of NF-κB from nuclei. This applies to an inhibitor of the nuclear transport of NF-κB, the peptide SN50 43 , as well as to small molecule inhibitors of IKK, BAY11-7082 44 and of the proteasome, bortezomib 45 ( Fig. 1A-D) . As expected, bortezomib stimulated the rapid accumulation of phosphorylated IκB in P39 cells (Fig. 1E) . Moreover, both BAY11-7082 and bortezomib caused the down-regulation of two anti-apoptotic NF-κB target genes,
Bcl-x L and c-IAP2 (Fig. 1F) . In this system, BAY11-7082 acted more rapidly than bortezomib (Fig. 1F) . Altogether these data indicate the presence of a transcriptionally active NF-κB heterodimer in the nucleus of P39 cells. The knock-down of p65 with two distinct small interfering RNAs (siRNAs) resulted in an increase of spontaneous apoptosis in P39 cells, in conditions in which sham transfection, transfection with a scrambled control (Co.) or knock-down of emerin expression had no significant pro-death activity (Fig. 1G) .
This indicates that P39 cells require NF-κB activation for survival.
NF-κB inhibition induces caspase-independent cell death in P39 cells. The inhibition of NF-κB using the two small molecule inhibitors BAY11-7082 ( Fig. 2A-C) and bortezomib ( Fig. 2D-F (Fig. 2G) , phosphatidylserine exposure (Fig. 2H) , and cell death (Fig. 2G, H) , although it did prevent bortezomib-induced nuclear fragmentation (karyorrhexis), as assessed by Hoechst 33324 staining and fluorescence microscopy ( Fig.   2I) , as an internal control of its efficacy. Moreover, z-VAD-fmk inhibited the activation of caspase-3 induced by BAY11-7082 or bortezomib (Fig. 2J, K) . This suggested that NF-κB inhibition induces bona fide apoptosis, accompanied by caspase activation, although this caspase activation is not required for cell death. In line with this interpretation, both BAY11-7082 or bortezomib were found to induce the mitochondrial release of cytochrome c (Cyt c) (Fig. 3A, D) and that of two caspase-independent death effectors, endonuclease G (EndoG) (Fig. 3B, E) and apoptosis inducing factor (AIF, Fig. 3C, F) . This translocation event could be visualized by different techniques, either by subcellular fractionation (Fig.   3G, H) or by immunofluorescence demonstrating that Cyt c, EndoG and AIF lost their colocalization with the mitochondrial marker Hsp60 and exhibited a rather diffuse staining pattern throughout the cell (Fig. 3A-C) . The release of these pro-apoptotic factors from mitochondria was not inhibited by z-VAD-fmk (Fig. 3) , although z-VAD-fmk did attenuate the degree of nuclear chromatin condensation (Fig. 3A-C) .
All-trans-retinoic acid (ATRA) and vitamin D 3 induced myeloid differentiation of P39 cells, leading to the expression of CD11b 46 . CD11b induction was not influenced by z-VAD-fmk (Fig. 4A) . Neither of these agents inhibits NF-κB (Fig. 1A) . ATRA (but not vitamin D 3 )
caused delayed cell death after 72 hours of incubation. This differentiation-induced cell death was inhibited by z-VAD-fmk (Fig. 4B, C) . At 24 hours, when neither of the differentiating agents induced apoptosis, they partially reduced the pro-apoptotic effect of BAY11-7082 or bortezomib (Fig. 4D, E) , although they lost their anti-apoptotic effect upon prolonged incubation (Fig. 4F, G) . Thus, BAY11-7082 or bortezomib can kill both undifferentiated and differentiating P39 cells.
For (Fig. 5A) . NF-κB activation in high-risk MDS was as intense as in MDS/AML samples (Fig. 5A) . Immunofluorescence detection of p65, performed on freshly collected bone marrow cells, correlated with the EMSA data (that include a supershift of p65, as detectable in nuclear extracts from purified
CD34
+ cells from high-risk MDS patients). Purified CD34 + or CD33 + cells from high-risk (but not from low-risk) MDS patients exhibited the nuclear translocation of p65 as well as EMSA-detectable NF-κB. This is shown for representative patients in Fig. 5B and quantified for a cohort of 18 patients in Fig. 5C . We found that there was a positive correlation between the percentage of blasts in MDS bone marrow samples and the frequency of CD34 + or CD33 + cells with nuclear p65 (Fig. 5C) . To address the question whether NF-κB activation would be restricted to the mutated cancer stem population and its derivatives or whether it would also affect non-mutated, normal cells in the bone marrow, we combined the immunohistochemical detection of p65 with the detection of chromosomal aberrations by FISH, at the single-cell level. Using this technique, we found that cells with nuclear p65 possessed cytogenetic alterations when patients with trisomy 8 or monosomy 7
were analyzed (Fig. 5D) (Fig. 5E) . The correlation between blast counts and nuclear p65 translocation was observed irrespective of the underlying cytogenetic alteration or the degree of cytopenias ( Table 1,2) . Importantly, we found that p65 translocation to the nucleus correlated with disease progression in a longitudinal study performed on four patients (Fig. 5F) . Altogether, these findings indicate a strong, constitutive NF-κB activation restricted to the blast population carrying cytogenetic aberrations.
NF-κB inhibition triggers the mitochondrial death pathway in MDS cells. If NF-κB acts
as an anti-apoptotic factor in MDS, its inhibition should precipitate the cell death of MDS blasts ex vivo. BAY11-7082 or bortezomib abolished NF-κB activation when added to bone marrow samples from high-risk MDS patients (Fig. 6A) . Simultaneously, BAY11-7082 or bortezomib-treated cells manifested the mitochondrial release of Cyt c, EndoG and AIF, correlating with chromatin condensation, as determined by immunofluorescence, both in CD34 + (Fig. 6B) and CD33 + cells (Fig. 6C) . Cytofluorometric analyses confirmed that BAY11-7082 and bortezomib enhanced cell death when added to bone marrow samples from high-risk MDS patients (Fig. 7A, C) . However, neither of the two NF-κB inhibitors did enhance the elevated spontaneous apoptosis affecting low-risk MDS samples (Fig. 7 A, C), in accord with the fact that low-risk MDS patients exhibit a low level of NF-κB activation, correlating with high spontaneous apoptosis (Fig. 7B) . Altogether, these data indicate that NF-κB inhibition can trigger the death of MDS blasts through a mitochondrial pathway involving the release of caspase activators and caspase-independent death effectors.
Concluding remarks
The data contained in this article indicate that NF-κB is activated within blasts found in MDS bone marrow samples. The strong correlation between blast counts and p65
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From translocation (Fig. 5E ) suggests that this latter parameter can be used as a surrogate marker of disease progression. In line with this hypothesis, high-risk MDS exhibit a higher frequency of cells with nuclear p65 (Fig. 5B, C) and more intense bands reflecting NF-κB activation in EMSA (Fig. 5A, B) , as compared to low-risk MDS. Thus, high-risk MDS behaves like post-MDS AML (Fig. 5A, C) Table 1 and Fig 5A, C) , and NF-κB NF-κB activates multiple target genes 54 , an important fraction of which exerts anti-apoptotic and proliferative functions. Low-risk MDS, in which NF-κB is not activated, is characterized by an enhanced apoptotic turnover of differentiating bone marrow cells 55 56 . In contrast, high-risk MDS with low intramedullar apoptosis 57 58 demonstrates NF-κB activation. It is tempting to speculate that the inverse correlation between apoptosis and NF-κB activation could reflect (one of) the mechanism(s) through which apoptosis is suppressed in high-risk MDS. In favor of this interpretation, we found that suppression of NF-κB by an IKK inhibitor or by a proteasome inhibitor enhanced apoptosis in high-risk MDS bone marrow cells ex vivo, yet had no such effect on low-risk MDS (Fig. 6-7) . Thus, high risk MDS blasts isolated ex vivo responded to BAY-7082 and bortezomib by apoptosis (Fig.   6,7) , in a similar fashion as the P39 cell line, which was isolated from the blood of a highrisk MDS patient 42 . Both freshly isolated MDS blasts and P39 cells succumbed to NF-κB inhibition without the need of additional cytotoxic stimuli. Both inhibited constitutive NF-κB activation with p65 translocation to the nucleus ( Fig. 1 B-D, Fig. 6 A) , which is not curtailed by differentiation induced in vitro (Fig; 1A, Fig. 4 ) or in vivo (Fig. 5B ) to CD11b-expressing or CD33-expressing myeloid cells, respectively. Moreover, this constitutive NF-κB activation was fully blocked by BAY11-7082 or bortezomib in patient-derived MDS blasts (Fig. 6 A) and in the P39 cell line (Fig. 1A-D) . Both primary MDS cells and P39 cells manifested mitochondrial changes culminating in the release of cytochrome c, AIF, and endonuclease G (Fig. 3, Fig. 6 ), as well as bone fide apoptosis with nuclear pyknosis and karyorrhexis (Fig. 2I, Fig. 6 ), when NF-κB was inhibited. Although caspase inhibition could prevent advanced chromatin condensation (Fig. 2I) , it had no or little effect on the irreversible loss of vital cellular functions (Fig. 2) , in accord with the fact that caspase inhibition also failed to suppress the mitochondrial release of the two caspase-independent death effectors AIF and EndoG (Fig. 3) .
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Altogether, these data suggest that NF-κB is vital for MDS blasts and that NF-κB inhibition might constitute a strategy for the eradication of such cells. Thus bortezomib or alternative, more-specific NF-κB inhibitors that are being developed might be tested alone or in combination with other agents for the treatment of MDS. figure) , were subjected to immunofluorescence analyses, showing an increase in p65 translocation to the nucleus. Blast counts and p65 translocation were correlated using the Spearman correlation model. , -7  14  3  3  RAEB-2  54  45, XX, -7  19  2  3  RAEB-2  55  45, XX, -7  48  1  MDS/AML  56  complex  17  2  3  RAEB-2  57  complex  19  3  3  RAEB-2 RA, refractory anemia; RCMD, refractory cytopenia with multilineage dysplasia; RAEB, refractory anemia with excess of blasts (5% to 9% BM blasts RAEB-1, 10%-19% BM blasts RAEB-2); 5q syndrome, MDS associated with isolated del(5q)
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